Transcutaneous immunization: T cell responses and boosting of existing immunity

被引:59
作者
Hammond, SA
Walwender, D
Alving, CR
Glenn, GM
机构
[1] Walter Reed Army Inst Res, Dept Membrane Biochem, Silver Spring, MD 20910 USA
[2] IOMAI Corp, Washington, DC 20037 USA
关键词
tetanus toxoid; transcutaneous immunization; vaccine;
D O I
10.1016/S0264-410X(00)00506-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Transcutaneous immunization (TCI) is a novel immunization strategy by which antigen and adjuvant are applied topically to intact, hydrated skin to induce potent antibody and cell-mediated immune responses specific for both the antigen and the adjuvant. Using tetanus toroid as a model antigen, we examined the T cell response to tetanus toroid after topical immunization with a variety of adjuvants. TCI readily induced systemic antigen specific T cell responses with a mixed Th1/Th2 phenotype but with a Th2 bias. We also investigated whether priming by the intramuscular route, which is known to induce T cell memory, could be followed by a boosting immunization on the skin to induce secondary responses. TCI could augment existing immunity, but interestingly, this strategy induced potent responses only if the antibody titer was low at the time of TCI boosting. These and previous observations suggest that TCI follows known immunological principles that govern other routes of vaccine delivery. Furthermore. booster immunization using tetanus toroid may provide a useful model for further development of important patch and formulation concepts for TCI, and act as an early candidate for validating product feasibility of TCI in humans. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2701 / 2707
页数:7
相关论文
共 33 条
  • [1] Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery
    Babiuk, S
    Baca-Estrada, M
    Babiuk, LA
    Ewen, C
    Foldvari, M
    [J]. JOURNAL OF CONTROLLED RELEASE, 2000, 66 (2-3) : 199 - 214
  • [2] BARRY BW, PERCUTANEOUS ABSORPT, P33
  • [3] Bouloc A, 1999, EUR J IMMUNOL, V29, P446, DOI 10.1002/(SICI)1521-4141(199902)29:02<446::AID-IMMU446>3.0.CO
  • [4] 2-A
  • [5] LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp.
    Chong, C
    Friberg, M
    Clements, JD
    [J]. VACCINE, 1998, 16 (07) : 732 - 740
  • [6] DNA-based immunization by in vivo transfection of dendritic cells
    Condon, C
    Watkins, SC
    Celluzzi, CM
    Thompson, K
    Falo, LD
    [J]. NATURE MEDICINE, 1996, 2 (10) : 1122 - 1128
  • [7] Fletcher M A, 2000, EXS, V89, P69
  • [8] Gagliardi MC, 2000, EUR J IMMUNOL, V30, P2394, DOI 10.1002/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO
  • [9] 2-Y
  • [10] Glenn G M, 1999, Expert Opin Investig Drugs, V8, P797, DOI 10.1517/13543784.8.6.797